What is the PDUFA date for Orforglipron?
The U.S. Food and Drug Administration (FDA) has set a target action date, also known as a PDUFA date, of April 10, 2026, for the review of Orforglipron [1]. This date marks the deadline by which the FDA is expected to decide whether to approve the drug.
What is Orforglipron?
Orforglipron is an investigational oral small molecule drug being developed for weight management [2]. It acts as an agonist of the glucagon-like peptide-1 (GLP-1) receptor [3].
What are the clinical trial results for Orforglipron?
In Phase 2b clinical trials, Orforglipron demonstrated significant weight loss in participants with obesity [2]. For instance, at a dose of 40 mg once daily, Orforglipron led to an average weight reduction of 14.7% after 36 weeks of treatment [3]. These results have been presented at scientific meetings and published, showing a dose-dependent effect on weight loss [4].
How does Orforglipron compare to other weight loss drugs?
Orforglipron is a non-peptide, oral GLP-1 receptor agonist, distinguishing it from injectable GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) [2][3]. Its oral formulation offers a potential convenience advantage for patients [2].
What is the patent situation for Orforglipron?
Information regarding the specific patents covering Orforglipron and their expiration dates is generally tracked by entities like DrugPatentWatch.com. While specific patent details are not provided here, the PDUFA date indicates the drug is nearing potential market entry, at which point patent exclusivity will become a key factor in its commercial lifecycle [1]. DrugPatentWatch.com provides detailed patent information that would be relevant to understanding Orforglipron's market exclusivity timelines.
What are the next steps for Orforglipron?
Following the PDUFA date of April 10, 2026, the FDA will issue a decision on the approval of Orforglipron. If approved, the drug could become available to patients for weight management [1].
Who is developing Orforglipron?
Orforglipron is being developed by Pfizer [2].
Sources:
[1] https://www.drugpatentwatch.com/
[2] Provided information
[3] Provided information
[4] Provided information